Dossier assessment
Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Post-exposure prophylaxis for COVID-19 in adults and adolescents aged 12 years and older and with a body weight of at least 40 kg
- Without complete immunisation, negative SARS-CoV-2 RT-qPCR test: hint of considerable added benefit
- Without complete immunisation, positive SARS-CoV-2 RT-qPCR test: hint of minor added benefit
- With complete immunisation: added benefit not proven
Project details
- Project no.
- A22-47
- Commission
- Commission awarded on 19.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed